Noile-Immune Biotech Inc.
Notice Regarding Large-Scale Exercise of Stock Acquisition Rights with Exercise Price Adjustment Clause
A large-scale exercise of stock acquisition rights occurred. During the period from October 6, 2026 to October 21, 2026, the number of shares to be delivered was 1,250,000 shares, reaching 12.5% of the total issued. Unexercised stock acquisition rights decreased to 87,500 units. The number of issued shares in the relevant month was 43,399,118 shares (of which treasury shares: 125 shares).
Key Figures
- Number of shares to be delivered: 1,250,000 shares
- Number of exercised stock acquisition rights: 12,500 units (12.5% of total issued)
- Unexercised stock acquisition rights: 87,500 units
- Number of issued shares: 43,399,118 shares (of which treasury shares: 125 shares)
AI要約
Overview of Large-Scale Exercise
Noile-Immune Biotech Inc. announced that a large-scale exercise occurred for stock acquisition rights with an exercise price adjustment clause issued on October 5, 2026. From October 6 to October 21, the number of shares to be delivered during the period was 1,250,000 shares, which corresponds to approximately 12.5% of the total issued. Meanwhile, the number of unexercised rights for the relevant month decreased from 100,000 units to 87,500 units.
Share Issuance Status and Dilution Impact
This large-scale exercise increases the number of delivered shares and may create dilution pressure for existing shareholders. The published number of issued shares is 43,399,118 shares (of which treasury shares: 125 shares). The degree of dilution may vary depending on future exercise activity.
Noile-Immune Biotech Inc.
Company overview · Stock price · Financial data · All IR
